QUOTE AND NEWS
FiercePharma  Apr 30  Comment 
Novartis is doing a complete U-turn on an OTC plant in Switzerland that 18 months ago was going to get the old heave-ho along with the people who worked there. Now the drugmaker says it will invest €150 million in the facility and anoint it a...
Wall Street Journal  Apr 30  Comment 
The auction of Brazilian drug maker Aché, which has drawn the interest of Novartis and Abbott Laboratories, has stalled because of a disagreement among the company's family owners.
Market Intelligence Center  Apr 30  Comment 
Novartis AG (NYSE: NVS) closed Monday's trading session at $73.74. In the past year, the stock has hit a 52-week low of $51.20 and 52-week high of $74.22. Novartis AG (NVS) stock has been showing support around $73.39 and resistance in the $74.19...
FiercePharma  Apr 29  Comment 
It's not often that the U.S. Justice Department delivers a one-two punch against a Big Pharma company. And it isn't often that prosecutors get to use the word "Hooters" in a legal complaint. But that's just what happened last week, when the feds...
Benzinga  Apr 29  Comment 
Incyte Corporation (NASDAQ: INCY) announced today that it has earned a $25.0 million milestone payment from Novartis based on the formal initiation of a Phase II clinical trial evaluating c-MET inhibitor INC280 (formerly INCB28060) as monotherapy...
Stock Blog Hub  Apr 27  Comment 
The US Food and Drug Administration (FDA) recently released briefing documents ahead of the review by its Pulmonary-Allergy Drugs Advisory Committee of the New Drug Application (NDA) of Theravance/Glaxo’s (THRX/GSK) candidate FF/VI...
Forbes  Apr 27  Comment 
Twice this past week, the US Department of Justice filed lawsuits alleging Novartis paid kickbacks to boost prescriptions and caused federal healthcare programs to pay for medicines based on false claims. One complaint seeks damages and civil...
New York Times  Apr 27  Comment 
The government joined a whistle-blower lawsuit that said a unit of Novartis paid millions to doctors in exchange for prescribing its drugs.     
Wall Street Journal  Apr 26  Comment 
Federal prosecutors accused the U.S. unit of Novartis of paying kickbacks and providing lavish dinners to doctors to encourage them to prescribe their brand-name drugs to treat hypertension and other maladies.
FiercePharma  Apr 26  Comment 
Sanofi ($SNY) is not very popular among its peers today. Its decision last year to halve the cost of its colon cancer drug Zaltrap in the face of high-profile criticism has inspired more than a 100 top docs from around the world to protest the...




 

Fuerralz? That's marvelously good to know.

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki